The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel was recently approved to treat relapsed or refractory pediatric acute lymphoblastic leukemia. With a one-time infusion cost of $475,000, tisagenlecleucel is currently the most expensive oncologic therapy. We aimed to determine whether tisagenlecleucel is cost effective compared with currently available treatments.
The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel was recently approved to treat relapsed or refractory pediatric acute lymphoblastic leukemia. With a one-time infusion cost of $475,000, tisagenlecleucel is currently the most expensive oncologic therapy. We aimed to determine whether tisagenlecleucel is cost effective compared with currently available treatments.
Methods
Markov modeling was used to evaluate tisagenlecleucel in pediatric relapsed or refractory acute lymphoblastic leukemia from a US health payer perspective over a lifetime horizon. The model was informed by recent multicenter, single-arm clinical trials. Tisagenlecleucel (under a range of plausible long-term effectiveness) was compared with blinatumomab, clofarabine combination therapy (clofarabine, etoposide, and cyclophosphamide), and clofarabine monotherapy. Scenario and probabilistic sensitivity analyses were used to explore uncertainty. Main outcomes were life-years, discounted lifetime costs, discounted quality-adjusted life-years (QALYs), and incremental costeffectiveness ratio (3% discount rate).
Results
With an assumption of a 40% 5-year relapse-free survival rate, tisagenlecleucel increased life expectancies by 12.1 years and cost $61,000/QALY gained. However, at a 20% 5-year relapse-free survival rate, life-expectancies were more modest (3.8 years) and expensive ($151,000/QALY gained). At a 0% 5-year relapse-free survival rate and with use as a bridge to transplant, tisagenlecleucel increased life expectancies by 5.7 years and cost $184,000/QALY gained. Reduction of the price of tisagenlecleucel to $200,000 or $350,000 would allow it to meet a $100,000/QALY or $150,000/QALY willingness-to-pay threshold in all scenarios.
Conclusion
The long-term effectiveness of tisagenlecleucel is a critical but uncertain determinant of its cost effectiveness. At its current price, tisagenlecleucel represents reasonable value if it can keep a substantial fraction of patients in remission without transplantation; however, if all patients ultimately require a transplantation to remain in remission, it will not be cost effective at generally accepted thresholds. Price reductions would favorably influence cost effectiveness even if longterm clinical outcomes are modest.
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most commonly diagnosed pediatric malignancy. 1 Although treatment advances have driven 5-year survival rates to . 90%, the prognosis of refractory or relapsed disease is poor, and ALL remains a leading cause of death as a result of childhood cancer. 2, 3 Those who survive relapse typically require hematopoietic stem-cell transplantation (HSCT) to remain in remission. Chimeric antigen receptor (CAR) T cells represent a new class of cancer immunotherapies that genetically engineer patient T cells to target their disease. Unlike other currently available treatments for relapsed and refractory ALL, CAR T cells, through long-term persistence, may cure a patient's disease without transplant.
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In 2017, the US Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis, Basel, Switzerland) as the first anti-CD19 CAR T-cell therapy for relapsed or refractory pediatric ALL. Although tisagenlecleucel-induced remission rates are promising compared with those of established therapies (. 80% v , 50%), only short-term follow-up data currently exist. [4] [5] [6] [7] [8] [9] Whether tisagenlecleucel is sufficient to cure relapsed or refractory disease without future transplantation remains unknown. Tisagenlecleucel also costs $475,000 (wholesale acquisition), which makes it the most expensive cancer therapy to date, and has expensive and potentially life-threatening adverse effects. 10 Given the high cost and broad applicability in other malignancies of tisagenlecleucel, a pressing question for policymakers, payers, patients, and clinicians is whether the cost of therapy represents reasonable value.
This study evaluated the cost effectiveness of tisagenlecleucel for relapsed and refractory pediatric ALL. As with other novel therapies considerable uncertainty exists about long-term outcomes, which in this case is durability of remission. To explore this uncertainty, we determined price thresholds at various levels of long-term effectiveness that would make tisagenlecleucel economically attractive. These results provide a robust framework for a value-based evaluation as long-term outcomes data become available.
METHODS
Modeling Without Long-Term Outcomes Data
Durability of remission is most clinically meaningful when assessed after several years; however, the median follow-up in tisagenlecleucel's pivotal trial was 13 months. 4, 11 Extrapolation of long-term outcomes from short-term data is common in oncologic modeling, but this approach can result in inaccurate assessments. 12 We addressed this uncertainty by evaluating three scenarios that cover a broad range of plausible long-term outcomes on the basis of observed variance and expert opinion (Data Supplement). The most optimistic scenario models 5-year relapse-free survival without HSCT at 40%, the intermediate scenario models 20%, and the most pessimistic scenario assumes that all patients who receive tisagenlecleucel experience a relapse within 5 years without transplant (0%; Fig 1) .
Although blinatumomab and the clofarabine-containing therapies also lack long-term follow-up data, most patients who receive these therapies experience a relapse without HSCT. Therefore, for these therapies, data from the transplantation literature inform long-term overall and relapse-free survival, which leads to relatively less uncertainty about long-term outcomes than tisagenlecleucel (Data Supplement).
Treatment Strategies
For each scenario, we compared tisagenlecleucel with three currently available treatments for relapsed and refractory pediatric ALL: blinatumomab; clofarabine, cyclophosphamide, and etoposide combination therapy (clofarabine combination); and clofarabine monotherapy.
Model Structure
We modeled a hypothetical cohort of US children with relapsed or refractory B-cell ALL by developing a Markov model that followed the cohort monthly over the patients' lifetimes (Fig 2) . For each treatment strategy, after receiving initial therapy, some patients achieve remission and the remainder are refractory or die. While in remission, patients may receive HSCT. Among patients with transplantations, first-time recipients and those who are minimal residual disease negative face more-favorable outcomes than those who received previous transplants or are minimal residual disease positive (Data Supplement). Patients who achieve 5 years of continuous remission are considered effectively cured and face a very low probability of relapse (and decreased lifespan compared with the general population). 11, 13 Upon relapse, patients receive palliative chemotherapy until death.
Blinatumomab and the clofarabine-containing therapies are generally insufficient to ensure durable long-term remission in relapsed disease, and additional therapy (ideally transplantation) is required. Therefore, we modeled these therapies as bridges to transplantation. In the month after initial remission, a proportion of patients proceed immediately to HSCT. This proportion was derived by pooling data from blinatumomab and clofarabine studies using a meta-analysis with random effects (Data Supplement). Those for whom transplantation is unavailable instead receive a 2-year course of consolidation, intensification, continuation, and maintenance chemotherapy 14 (Data Supplement). In our main analyses, we assume the nontransplantation 5-year relapse-free survival rates are , 10% and increase to 25% in scenario analysis (Data Supplement).
The treatment course for tisagenlecleucel deviates from this model structure in two ways. First, the model reflects the pivotal trial in which approximately 18% of patients did not complete initial tisagenlecleucel infusion, 4 due to a major adverse event, manufacturing failure, or death. We considered patients who failed to complete infusion due to a major adverse event unable to tolerate additional therapy, and these patients' survival probabilities were modeled as such 15 (Data Supplement). Patients who were unable to receive tisagenlecleucel as a result of manufacturing failure instead received blinatumomab. Second, unlike the blinatumomab or clofarabine therapies, tisagenlecleucel is potentially curative. Accordingly, after patients achieved remission with tisagenlecleucel in our model, a minority received transplantation or alternative therapy (modeled as consolidation, intensification, continuation, and maintenance chemotherapy) at rates and times that reflect those observed in the pivotal trial 4 (Data Supplement). If tisagenlecleucel does not produce sustained remission without transplantation, its ability to induce short-term remissions may render it a clinically useful bridging therapy. Therefore, we also modeled tisagenlecleucel as a bridge to transplantation (similar to the blinatumomab and clofarabine therapies) under a 0% transplantation-free 5-year relapsefree survival scenario.
Model Inputs and Calibration
Rates of remission, survival, and relapse under each treatment strategy were informed by trial evidence using model calibration. We identified eight trials, all single arm: three tisagenlecleucel (one pivotal, two supportive), one blinatumomab, three clofarabine combination therapy, and one clofarabine monotherapy. [4] [5] [6] [7] [8] [9] 16 When multiple trials were available, we aggregated data to create a unified survival curve.
We calibrated the model's inputs using a constrained optimization algorithm to match the overall and relapse-free survival curves from the trials. 17 To model each of the three tisagenlecleucel 5-year relapse-free survival scenarios, we calibrated the model inputs to match the unified overall survival curve in the trials as well as a modified relapse-free survival curve that terminated at 40%, 20%, and 0% at 5 years (Fig 1) . Technical details are provided in the Data Supplement. We estimated the effects of grade 3 to 4 adverse events (including cytokine release syndrome and graftversus-host disease) and secondary malignancies by modeling their incidences, costs, and quality-of-life decrements from trials and retrospective data 13,18 (Data Supplement).
Costs and Utilities
Our analysis adopts a US health care payer perspective and accounts for direct health care costs, including drugs, therapy administration, adverse events, HSCT, and follow-up care [19] [20] [21] [22] [23] [24] (Table 1 ; Data Supplement). Our model reflects the outcome-based payment scheme Novartis was using at the time of writing wherein the payer is responsible for tisagenlecleucel's cost only if the patient achieves initial remission.
10 Related costs, including pre-infusion chemotherapy, administration, and complications, were incurred regardless of whether the patient achieved remission. Follow-up costs after tisagenlecleucel assume 5 years of B-cell aplasia that requires monthly intravenous Modeled overall and relapse-free survival curves for three tisagenlecleucel long-term remission scenarios. Modeled (A) overall and (B) relapse-free survival curves for patients with relapsed or refractory pediatric B-cell acute lymphoblastic leukemia who receive tisagenlecleucel (time 0) superimposed on Kaplan-Meier curves that combine one pivotal and two supportive clinical trials. Dotted lines indicate combined 95% CIs. Tick marks on the Kaplan-Meier curves indicate censored events. On the basis of the Kaplan-Meier curves presented in the three tisagenlecleucel trials, patients represented by the relapse-free survival curve were censored if they received alternative treatments (including stem-cell transplantation) while in remission, whereas overall survival includes all patients. For clarity, the 95% CIs around the modeled scenarios are not shown; these can be seen in the Data Supplement. immunoglobulin infusions for patients in remission. Costs were inflation adjusted to 2017 US dollars. 38 We used estimates from the leukemia and HSCT literature to assign preference-weighted utilities to each health state modeled.
30-37 When preference-weighted data did not exist, we used established methodologies to estimate utilities from oncology-specific quality-of-life scales. 35, 39, 40 Additional details are provided in the Data Supplement.
Main Outcomes
Outcomes were life-years, costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ie, incremental cost per QALY gained) over a lifetime horizon. 41 Costs and QALYs were discounted at 3% annually. 41, 42 We defined the long-term effectiveness and prices at which tisagenlecleucel would be cost effective at three willingness-to-pay (WTP) thresholds: $50,000/QALY, $100,000/QALY, and $150,000/QALY.
Sensitivity Analyses
To assess how variations in model input altered our conclusions, we performed one-way sensitivity analyses. We also performed several scenario analyses, including alternative payment agreements varying the remission duration threshold that triggers payment for tisagenlecleucel, modeling the pivotal trial for tisagenlecleucel alone (without the two supportive trials), assuming no pre-infusion deaths in the tisagenlecleucel arm, allowing 5-year nontransplantation relapse-free survival rates for non-CAR T-cell therapies to be as high as 25%, and comparing tisagenlecleucel with palliative chemotherapy.
We performed probabilistic sensitivity analyses in which we simultaneously sampled model inputs 1,000 times from uncertainty distributions (Table 1 ). To test model stability, we also modeled our base-case scenario with 10,000 simulations.
Our model was built using TreeAge Pro Healthcare 2018, R1 release (TreeAge Software, Williamstown, MA). Calibration and statistical analyses j Utilities (quality-of-life estimates) while patients receive treatment are modeled as dependent on what treatment is received (and associated toxicities) rather than whether the patient achieves remission or has refractory disease. k Postinduction chemotherapy is modeled as a 2-year course of chemotherapy to the fraction of patients initially treated with blinatumomab or a clofarabine-containing therapy who achieve remission but are unable to receive a transplantation. This is divided into 2 months of consolidation, 2 months of intensification, 2 months of continuation, and 18 months of maintenance (see Data Supplement).
jco.org Abbreviations: ICER, incremental cost-effectiveness ratio (incremental cost per quality-adjusted life-year); QALY, quality-adjusted life-year; WTP, willingness to pay.
*Refers to the percentage of patients infused with tisagenlecleucel modeled to survive to 5 years without relapse in the absence of hematopoietic stem-cell transplantation. Patients in the tisagenlecleucel scenarios receive a transplantation at the empirically observed low rate and times seen in the pivotal trial. †Modeled under the assumption that in the absence of transplantation, 0% of patients survive to 5 years without relapse. In this scenario, patients who achieve remission are modeled as receiving hematopoietic stem-cell transplantation at an equivalent rate to comparator treatment arms. ‡A treatment scenario is dominated if it results in inferior outcomes and higher costs compared with the reference treatment.
were performed with R software, version 3. 
RESULTS
Base-Case Analysis
Tisagenlecleucel resulted in longer life expectancies than other therapies at 5-year relapse-free survival rates . approximately 5%. Patients treated with tisagenlecleucel experienced life expectancies of 20.6, 12.3, and 5.95 years at 5-year relapse-free survival rates of 40%, 20%, and 0%, respectively. Blinatumomab, clofarabine combination therapy, and clofarabine monotherapy yielded average life expectancies of 8.6, 8.6, and 7.6 years, respectively. Tisagenlecleucel was the most expensive treatment strategy at $548,000 to $599,000. The comparators were less expensive at $282,000 to $374,000 (Table 2) . Blinatumomab resulted in superior outcomes at lower costs than both clofarabine-containing arms.
Tisagenlecleucel's economic value was strongly influenced by its long-term outcomes. At 40% 5-year relapse-free survival, tisagenlecleucel resulted in an additional 5.07 QALYs gained at a cost of $61,000/QALY compared with blinatumomab. At 20% 5-year relapse-free survival, tisagenlecleucel resulted in an additional 1.80 QALYs gained at a cost of $151,000/QALY. At 0% 5-year relapse-free survival, blinatumomab had superior outcomes at a lower cost than tisagenlecleucel (Table 2 ; Data Supplement). At its current price, tisagenlecleucel cost , $100,000/QALY down to a 5-year relapse-free survival rate of approximately 30% and , $150,000/QALY down to a rate of approximately 25% (Fig 3) .
Reducing tisagenlecleucel's price increases its cost effectiveness, even if long-term outcomes are modest. At a 5-year relapse-free survival rate of 20%, a price reduction to approximately $325,000 or $450,000 would meet $100,000/QALY or $150,000/QALY WTP thresholds, respectively. Tisagenlecleucel is not cost-effective compared with blinatumomab at any price below a 5-year relapse-free survival rate of approximately 5% (Fig 3) .
In a worst-case scenario in which all patients who receive tisagenlecleucel eventually relapse without transplantation, use of the therapy as a bridge to transplantation resulted in an increased life expectancy (5.7 years) compared with blinatumomab (2.35 QALYs gained at $184,000/QALY). To meet a $100,000/QALY or $150,000/QALY threshold would require reductions in price to approximately $200,000 or $350,000, respectively.
Sensitivity Analyses
In one-way sensitivity analyses, two model parameters rendered tisagenlecleucel cost effective by assuming modest long-term outcomes: reductions in price and a low discount rate. In a bridgeto-transplantation scenario, increasing the proportion of patients who receive a transplantation (among those who achieve remission) from 0.55 to 0.75 improved tisagenlecleucel's economic value, but it would not make it cost effective. Tisagenlecleucel's economic value was substantially worse if costs and benefits were taken into account over 15 years rather than through each individual's lifespan. Several parameters moderately worsened tisagenlecleucel's economic value: standardized mortality ratio after long-term remission, cost of care after long-term remission, and cost of care for grade 4 cytokine release syndrome. Our assessment of tisagenlecleucel's cost effectiveness was not materially changed with variation in other short-term costs (Data Supplement; Fig 4) .
In probabilistic sensitivity analyses, tisagenlecleucel at a 5-year relapse-free survival rate of 40% was cost effective in 99.3%, 98.7%, and 6.0% of simulations at WTP thresholds of $150,000, $100,000, and $50,000, respectively. Tisagenlecleucel at a 5-year relapse-free survival rate of 20% was cost effective in 53.1%, 6.5%, and 0% of simulations at equivalent thresholds. At a 5-year relapse-free survival rate of 0% and in the absence of transplantation, tisagenlecleucel consistently produced inferior outcomes to blinatumomab at a higher cost (Table 2 ; Data Supplement).
Scenario Analyses
The current outcomes-based payment agreement did not materially affect tisagenlecleucel's economic value compared with Two-way sensitivity analysis: cost effectiveness of tisagenlecleucel compared with blinatumomab by 5-year relapse-free survival rate and price. At 2018 US prices, tisagenlecleucel cost , $100,000/qualityadjusted life-year (QALY) down to a 5-year relapse-free survival rate of approximately 30%. If 5-year relapse-free survival rates are approximately , 20%, it is not cost effective at commonly accepted thresholds. Below 5-year relapse-free survival rates of approximately 5%, outcomes are inferior to blinatumomab. Price reductions favorably influence cost effectiveness, even if long-term clinical outcomes are modest. In the bridge-totransplantation scenario, in the absence of transplantation, 0% of patients survive to 5 years without relapse. In this scenario, patients who achieve remission are modeled as receiving hematopoietic stem cell transplantation at an equivalent rate to comparator treatment arms.
jco.org a traditional agreement that requires all patients to pay. However, alternative payment agreements resulted in the therapy becoming more economically attractive. Increasing the remission duration threshold that triggers payer responsibility from any initial remission to 7 months of remission allowed tisagenlecleucel to meet a $100,000/QALY WTP threshold at 40% and 20% 5-year relapsefree survival rates and a $150,000/QALY WTP threshold in a bridge-to-transplantation scenario (Data Supplement).
The following scenarios did not change our assessment of tisagenlecleucel's economic value: assuming no infusion failure as a result of death or manufacturing, comparing tisagenlecleucel directly with palliative chemotherapy, using only tisagenlecleucel's pivotal trial to inform outcomes, or allowing 5-year nontransplantation relapse-free survival rates for non-CAR T-cell therapies to be as high as 25%. The results were robust to analyses with 10,000 simulations (Data Supplement).
DISCUSSION
We find that tisagenlecleucel may provide substantial survival gains for children with relapsed or refractory ALL compared with currently available therapies. However, we also show that at its current price and payment structure, the long-term effectiveness of tisagenlecleucel (ie, the ability to keep a substantial fraction of patients in remission without transplantation) is an important but uncertain determinant of its cost effectiveness.
At our most optimistic assumptions (40% 5-year relapse-free survival), tisagenlecleucel would result in considerable survival gains (12.1 life-years) while representing good economic value (, $100,000/ QALY). In a field where developments often are incremental, these results would represent an important advance. However, as we modeled progressively lower long-term effectiveness (20% to 0% 5-year relapse-free survival), its economic value diminished. If tisagenlecleucel fails to meet the goal of transplantation-free cure, clinicians may use it as a bridge to transplantation. This worst-case scenario would lead to an increased life expectancy (5.7 years), but at a cost of $184,000/QALY, it would not meet commonly accepted thresholds for cost effectiveness.
Tisagenlecleucel's robust short-term outcomes make it a critical therapy for children with relapsed or refractory ALL. However, our results suggest that at tisagenlecleucel's current price and payment structure, its economic value is uncertain. This uncertainty may lead payers to choose not to cover tisagenlecleucel or to only cover it for certain patient populations. Our analysis indicates two potential ways payers may be more willing to assume the risk of suboptimal long-term clinical outcomes. The first is a lower price. At a price of $200,000 or $350,000, tisagenlecleucel would meet a , $100,000/QALY or , 150,000/QALY threshold, even in a worst-case scenario in which all patients experience relapse and tisagenlecleucel is used as a bridge to transplantation. As additional outcomes data are reported, this price could be adjusted to reflect increased certainty about tisagenlecleucel's longterm effectiveness.
Some payers, patient advocates, and pharmaceutical companies support outcomes-based pricing for tisagenlecleucel, which ties reimbursement to clinical outcomes. This theoretically allows all stakeholders to share in the financial risk of a therapy with uncertain outcomes and therefore increases its economic attractiveness (and the likelihood that the payer will cover the therapy). In Novartis'currently proposed arrangement, the payer is responsible for the price of tisagenlecleucel only if the patient achieves initial remission.
10 However, because of tisagenlecleucel's high initial remission rates, this does not materially mitigate risk compared with a traditional payment model. If the arrangement is changed such that payment occurs only if the patient achieves 7 months of remission, tisagenlecleucel would meet a , $100,000/ QALY threshold at a 40% and 20% 5-year relapse-free survival rate and a , $150,000/QALY threshold in a worst-case, bridge-totransplantation scenario (Data Supplement).
To our knowledge, this cost-effectiveness analysis is the first to explore the uncertainty of tisagenlecleucel's long-term effects in pediatric patients with ALL. The results are consistent with two non-peer-reviewed analyses, and our conclusions provide stakeholders with a deeper understanding of the determinants of tisagenlecleucel's cost effectiveness. 44, 45 We conclude from two other analyses that tisagenlecleucel would be cost effective at a WTP threshold of $100,000/QALY. However, the analyses followed the current standard oncologic modeling approach with the evaluation of only one long-term effectiveness scenario by extrapolating short-term data to predict future outcomes. This approach yielded a 5-year relapse-free survival rate estimate for tisagenlecleucel of approximately 42%. 44 Although this outcome is possible and produces similar economic results to our 40% relapsefree survival scenario, this assumption may be overly optimistic given the pivotal trial's short follow-up. 4 Although there will always be uncertainty assessing the economic value of a novel therapy in its early stages given the rapid rise of next-generation cancer therapies (and their prices), it is arguably more important than ever that patients, payers, and clinicians have access to reliable and robust cost-effectiveness data early on to inform their understanding of the therapy's economic value. We show that by modeling multiple plausible long-term outcome scenarios, including a worst-case scenario of zero transplantationfree long-term remissions, we can provide an account of the range of tisagenlecleucel's likely economic value. Moreover, we demonstrate the effect of changes in price or payment structure on its economic value if long-term clinical outcomes are modest.
This study has several limitations. No high-quality long-term clinical outcomes data exist for tisagenlecleucel. We addressed this limitation by modeling multiple long-term effectiveness scenarios, including one where all patients eventually experience relapse. All trials for relapsed or refractory pediatric ALL were single-arm studies, which limited a direct comparison between treatment not receive a transplantation eventually experience relapse. Among patients who achieve initial remission, the fraction who receive a transplantation is identical in all arms. The dotted line depicts the incremental cost-effectiveness ratio of the base-case. The gray lines depict the three willingness-to-pay (WTP) thresholds evaluated: $50,000/quality-adjusted life-year (QALY), $100,000/QALY, and $150,000/QALY. Incremental cost-effectiveness ratios (ICERs) lower than a given threshold can be interpreted as the intervention being cost effective at that threshold. admin, administration; CRS, cytokine release syndrome; HSCT, hematopoietic stem-cell transplantation.
(Continued) jco.org arms. We compared tisagenlecleucel with the next most optimal therapy in a conservative manner because patients enrolled in tisagenlecleucel trials had poorer baseline prognostic characteristics than those in comparator trials (Data Supplement). Although we evaluated two extremes of using tisagenlecleucel-with minimal transplantation, and as a bridge to transplantation-both treatment strategies as well as intermediates likely will coexist eventually, which may change tisagenlecleucel's cost effectiveness. As strategies are developed that incorporate alternative timing of transplantation, these can be evaluated in future cost-effectiveness analyses. As with all modeling studies, data availability limited our analysis. Several uncertain inputs would worsen tisagenlecleucel's economic value if more pessimistic than modeled, including cost of cytokine release syndrome and costs and outcomes after cure. Other variations in cost did not materially influence tisagenlecleucel's cost effectiveness. We did not account for tisagenlecleucel's non-health care benefits in this analysis, such as future productivity, which may be substantial given the young age at which patients may be cured.
At tisagenlecleucel's current price and payment structure, its long-term clinical effectiveness is a critical determinant of its costeffectiveness. If tisagenlecleucel results in a substantial fraction of patients who achieve durable remission without transplantation, it would represent good economic value. However, its value diminishes under scenarios of lower long-term effectiveness. Price reductions of tisagenlecleucel or payment only for longer-term remissions would favorably influence cost-effectiveness, even if long-term clinical outcomes are modest.
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Disclosures provided by the authors are available with this article at jco.org. 
AUTHOR CONTRIBUTIONS
